### Edgar Filing: PTC THERAPEUTICS, INC. - Form 4

Check this box if no longer subject to Section 16. SECURITIES SECURITIES Number: Value of the section 16. Number: Section 16. SECURITIES Number: Section 16. Number: Section 16. SECURITIES Number: Section 16. Number: Section 16. SECURITIES Number: S								3235-0287 January 31, 2005 Iverage		
(Print or Type	Responses)									
ALDRICH RICHARD Symbol			THERAPEUTICS, INC.				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last)	(First) (Middle)		3. Date of Earliest Transaction Month/Day/Year) 03/07/2013				X_ Director10% Owner Officer (give titleOther (specify below)below)			
1365 MAIN	I STREET	03/07/2013								
(Street) 4. If Ame Filed(Mon WALTHAM, MA 02451			ate Original r)			6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(State) (Zip)	Table I - Non-l	Derivative Se	ecuritie	s Acq	uired, Disposed of	, or Beneficial	ly Owned		
1.Title of Security (Instr. 3)	any		Transaction(A) or Disposed of (D) Code (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)			
~		Code V	Amount	(D)	Price	(msu: 5 and 4)		See		
Common Stock	06/25/2013	С	583,333	А	<u>(1)</u>	583,333	Ι	Footnote $(2)$		
Common Stock	06/25/2013	Р	466,667	А	\$ 15	1,050,000	Ι	See Footnote $(2)$		
Common Stock	06/25/2013	Р	300,000	А	\$ 15	300,000	Ι	See Footnote $(3)$		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

#### Edgar Filing: PTC THERAPEUTICS, INC. - Form 4

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number orDerivative Acquired (A Disposed or (Instr. 3, 4,	Securities A) or f (D)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amo Underlying Secu (Instr. 3 and 4)	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	An Nu Sh
Series Four										
Senior Preferred Stock	<u>(1)</u>	03/07/2013		Р	583,333		<u>(1)</u>	(1)	Common stock	58
Stock Option (right to buy)	\$ 10.85	05/15/2013		Р	20,000		(4)	05/15/2023	Common stock	2
Series Four Senior Preferred Stock	ш	06/25/2013		C		583,333	<u>(1)</u>	<u>(1)</u>	Common stock	58

### **Reporting Owners**

Reporting Owner Name / Address	Relationships						
I B	Director	10% Owner	Officer	Other			
ALDRICH RICHARD 1365 MAIN STREET WALTHAM, MA 02451	Х						
Signatures							
/s/ Mark E. Boulding, attorney-in-fact	06/27/2013						
**Signature of Reporting Person	Date						

## **Explanation of Responses:**

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

#### Edgar Filing: PTC THERAPEUTICS, INC. - Form 4

Each share of Series Four Senior Preferred Stock converted automatically into one share of Common Stock upon the closing of PTC(1) Therapeutics, Inc.'s initial public offering without payment of further consideration. The Series Four Senior Preferred Stock had no expiration date.

Shares held by Longwood Fund LP. The managing members of Longwood Fund LP, including Mr. Aldrich, share voting and investment(2) power with respect to such shares. Mr. Aldrich disclaims beneficial ownership of the shares held by Longwood Fund LP except to the extent of any pecuniary interest therein.

Shares held by RA Capital Biotech Fund LP. The managing members of RA Capital Biotech Fund LP, including Mr. Aldrich, share(3) voting and investment power with respect to such shares. Mr. Aldrich disclaims beneficial ownership of the shares held by RA Capital Biotech Fund LP except to the extent of any pecuniary interest therein.

This option was granted on May 15, 2013 and vests over three years, with 8.33% of the shares underlying the option vesting on August
(4) 15, 2013 and an additional 8.33% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.